Also trades as: 0JBU.L (LSE) · $vol 0M
NTLA NASDAQ
Intellia Therapeutics, Inc.
1W: -2.8%
1M: -4.2%
3M: +3.4%
YTD: +22.3%
1Y: -56.5%
3Y: -58.5%
5Y: -91.4%
$12.28
+1.02 (+9.06%)
After Hours: $12.18 (-0.10, -0.86%)
Weekly Expected Move ±8.1%
$9
$10
$11
$12
$13
Credit Risk of going bust: higher than 68% of companies Debt: 4.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 99.1%), Intellia Therapeutics, Inc. would be worth roughly what it owes.
Total debt $73.4M against a stock market value of $1.58B.
Distance to default 3.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.7M (short-term plus half of long-term), stock volatility 96.2%; Altman Z'' -4.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 99.1%), Intellia Therapeutics, Inc. would be worth roughly what it owes.
Total debt $73.4M against a stock market value of $1.58B.
Distance to default 3.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $36.7M (short-term plus half of long-term), stock volatility 96.2%; Altman Z'' -4.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
FDA unveils rare disease initiative to enhance therapy development
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMD
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026
Could This Cathie Wood Stock Soar in 2027?
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
How Investors May Respond To Intellia Therapeutics Stock After Priority Review - simplywall.st
Cathie Wood's Ark weekly recap: buys Meta, gene-editing stocks while cutting Alphabet
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
3 Promising Genomics Stocks in the Spotlight in 2026
3 Promising Genomics Stocks in the Spotlight in 2026
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
Intellia rises on FDA priority review for one-time hereditary angioedema therapy
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Public Employees Retirement System of Ohio Invests $1.49 Million in Intellia Therapeutics, Inc. $NTLA
If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan
Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In - Yahoo Finance
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sector Update: Healthcare Stocks Decline Friday Afternoon
Intellia Therapeutics secures $400M loan facility
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA
41 new hires get Intellia stock awards that vest annually for 3 years - Stock Titan
Intellia Therapeutics (NTLA) Stock Could Be Fully Priced On Pipeline Hopes - simplywall.st
A gene-editing company gets $75 million now; Intellia can draw up to $225 million if it meets milestones. - Stock Titan
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026
Hsbc Holdings PLC Takes $1 Million Position in Intellia Therapeutics, Inc. $NTLA
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Biotech Breakout: What's in focus after Moderna's cancer win?
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Cathie Wood's ARK Goes On $27 Million SpaceX Shopping Spree
Intellia Therapeutics (NTLA) CEO sells shares around $13 - Stock Titan
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
Intellia (NTLA) Q2 2026 Earnings Call Transcript
Intellia (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Q2 Loss Widens to $106.6 Million as Lonvo-z Advances | NTLA Stock News - quiverquant.com
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
$NTLA stock is down 8% today. Here's what we see in our data. - quiverquant.com
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tesla, AMD, and SpaceX headline Cathie Wood's biggest H1 portfolio bets
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
This Stock Is Up 58% This Year. Is It too Late to Buy?
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
NTLA Stock Climbs As Phase 3 Wins Meet Extended Cash Runway - StocksToTrade
$NTLA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't
High Growth Tech Stocks To Watch In US June 2026
NTLA Stock | Intellia Shares At 160 Buy Now Or Wait? (ARebvdaUuh) - Fathom Journal
A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data Approaches - simplywall.st
CRISPR HAE therapy lonvo-z gets late-breaking EAACI 2026 slot - Stock Titan
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight - Seeking Alpha
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
High Growth US Tech Stocks To Watch In May 2026
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
High Growth Tech Stocks In The US For May 2026
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates